Gall Bladder Cancer
A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)
- Details
ClinicalTrials.gov ID:
NCT03773302
Diagnosis Type:
NA
USOR Number:
- Address
910 E 26th St, Suite 200
Minneapolis, MN 55404
P: (612) 884-6300